Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Chimerix Confirms Ongoing Negotiations With BARDA On Smallpox Medicine Contract

  • In its SEC filingChimerix Inc (NASDAQ:CMRX) announced that it had been aware of unusual trading activity in the Company's common stock. 
  • The Company believes the unusual trading activity may be attributable to statements regarding smallpox antiviral development and procurement contained in the Fiscal Year 2023 Congressional Justification for the Public Health & Social Services Emergency Fund.
  • Chimerix confirms that it remains in active negotiations with the Biomedical Advanced Research and Development Authority (BARDA) regarding a sole-source contract to develop and procure up to 1.7 million treatment courses of TEMBEXA. 
  • Related: Chimerix's CMX521 Antiviral Program Shows Potential Against COVID-19 In Preclinical Studies.
  • The Company currently expects to enter into the contract in Q2 of FY22.
  • The initial shipment of TEMBEXA (consistent with prior guidance of ($80-100 million) is to be procured and shipped to the Strategic National Stockpile soon after contract execution. 
  • Price Action: CMRX shares are up 0.21% at $4.70 during the premarket session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.